EP1003877A2 - Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus - Google Patents

Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus

Info

Publication number
EP1003877A2
EP1003877A2 EP98949901A EP98949901A EP1003877A2 EP 1003877 A2 EP1003877 A2 EP 1003877A2 EP 98949901 A EP98949901 A EP 98949901A EP 98949901 A EP98949901 A EP 98949901A EP 1003877 A2 EP1003877 A2 EP 1003877A2
Authority
EP
European Patent Office
Prior art keywords
dna
virus
protein
papillomavirus
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98949901A
Other languages
German (de)
English (en)
Inventor
Ethel-Michelle De Villiers Zur Hausen
Harald Zur Hausen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of EP1003877A2 publication Critical patent/EP1003877A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Definitions

  • Papillomaviruses means for their detection and for the therapy of diseases caused by them
  • the invention relates to a DNA which codes for a peptide of a papillomavirus main capsid protein or a papillomavirus genome. Furthermore, the invention relates to proteins encoded by the papilloma virus genome and antibodies directed against them, and to their use in diagnosis, therapy and vaccination.
  • HP viruses Human papilloma viruses
  • benign e.g. Warts, genital condylomas, and malignancies, e.g. Carcinomas of the skin and uterus, epithelial neoplasms (cf.zzy Hausen, H., Biochimica et Biophysica Acta (BBA) 1 288, (1 996), pages 55-78).
  • HP viruses are also being considered for the development of malignant tumors in the oropharyngeal area (cf.zzy Hausen, H., Curr. Top. Microbiol. Immunol. 78, (1 977), pages 1-30).
  • Papilloma viruses have an icosahedral capsid without a shell, in which a circular, double-stranded DNA molecule of approximately 7900 bp is present.
  • the capsid comprises a major capsid protein (L1) and a minor capsid protein (L2). Both proteins, coexpressed or L1 expressed alone, lead to the formation of virus-like particles in vitro (cf. Kirnbauer, R. et al., Journal of Virology, (1 993), pages 6929-6936).
  • Papilloma viruses cannot be propagated in monolayer cell culture. Their characterization is therefore extremely difficult, and the detection of papilloma viruses already creates considerable problems. This is particularly true for papilloma viruses in skin carcinomas.
  • the object of the present invention is therefore to provide an agent with which papilloma viruses, in particular in carcinomas of the skin, can be detected.
  • a means should also be provided to treat these papillomaviruses therapeutically.
  • the invention thus relates to a DNA coding for a peptide of a papillomavirus main capsid protein (L1), the peptide representing the amino acid sequence of FIGS. 1, 2, 3, 4, 5, 6 or 7 or one of these amino acid sequences different from one or more amino acids
  • Another object of the invention is a DNA coding for a peptide of a papillomavirus main capsid protein, the DNA being the base sequence of FIG. 1, 2, 3, 4, 5, 6 or 7 or one of which comprises a base sequence different from one or more base pairs
  • FIG. 2 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. This DNA was deposited as plasmid DL347 at DSMZ under DSM 1 1 605 on June 1, 1 997.
  • FIG. 3 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was obtained as plasmid DL369 at DSMZ under DSM 1 1 606 on June 1, 1 997 deposited.
  • FIG. 4 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. This DNA was deposited as plasmid GA1-3 with the DSMZ under DSM 1 1 607 on June 1, 1 997.
  • FIG. 5 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid GA3-1 at DSMZ under DSM 1 1 608 on June 1, 1 997.
  • FIG. 6 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid GA6-2 at DSMZ under DSM 1 1 609 on June 1, 1 997.
  • FIG. 7 shows the base sequence and the amino acid sequence derived therefrom of a DNA coding for a peptide from L1 of a papilloma virus. This DNA was deposited as plasmid GA9-4 with the DSMZ under DSM 1 1 61 0 on 1 June 2, 997.
  • the above DNA was compared to the DNA of known papilloma viruses. Sequence homology studies were carried out. A homology that is less than 90% shows a DNA according to the invention as a new HP virus.
  • the DNAs according to the invention have the following sequence homologies with known papilloma viruses:
  • the above DNA can be present in a vector or expression vector.
  • examples of such are known to the person skilled in the art.
  • these are e.g. pGEMEX, pUC derivatives, pGEM-T and pGEX-2T.
  • yeast z. B. pY1 00 and Ycpad l to name while for expression in animal cells e.g. pKCR, pEF-BOS, cDM8 and pCEV4 must be specified.
  • suitable cells in order to express the above DNA present in an expression vector.
  • suitable cells include the E.coii strains HB1 01, DH 1, x 1 776, JM 1 01, JM 1 09 and XLI-Blue, the yeast strain Saccharomyces cerevisiae and the animal cells L, NH-3T3, FM3A, CHO, COS, Vero, and Heia.
  • the person skilled in the art knows how the above DNA has to be inserted into an expression vector. He is also aware that the above DNA can be inserted in connection with a DNA coding for another protein or peptide, so that the above DNA can be expressed in the form of a fusion protein.
  • papilloma virus genome comprising the above DNA.
  • the term "papilloma virus genome” also includes an incomplete genome, i.e. Fragments of a papilloma virus genome comprising the above DNA. This can e.g. a DNA coding for L1 or a part thereof.
  • a common method can be used to provide the above papillomavirus genome.
  • a method comprising the following method steps is favorable: (a) isolation of the total DNA from a biopsy of epithelial neoplasm,
  • epithelial neoplasm encompasses any neoplasms of epithelial tissue in humans and animals. Examples of such neoplasms are warts, condylomas in the genital area and carcinomas of the skin. The latter are preferably used in the present case to isolate the above papillomavirus genome.
  • vector includes any vector suitable for cloning chromosomal or extrachromosomal DNA.
  • vectors include cosmids, such as pWE 15 and Super Cos1, and phages, such as ⁇ -phages, e.g. ⁇ ZAP Expressvector, ⁇ ZAPII Vector and ⁇ gt10 Vector.
  • i-phages are preferably used.
  • the above vectors are known and are available from Stratagene.
  • Papilioma virus genomes according to the invention can be integrated in chromosomal DNA or extrachromosomal. Methods are known to the person skilled in the art to clarify this. He also knows how to find the optimal restriction enzymes for cloning the papilloma virus genome. He's going to Orient genomes of known papilloma viruses. In particular, the person skilled in the art will observe the aforementioned HP viruses accordingly.
  • a papilloma virus genome designated DL314-G is described by way of example.
  • the total DNA is isolated from a biopsy of a basal cell carcinoma, cleaved with BamHI and separated electrophoretically in an agarose gel.
  • the agarose gel is then subjected to a blotting process, whereby the DNA is transferred to a nitrocellulose membrane.
  • This is used in a hybridization process in which the DNA from FIG. 1, possibly in combination with a DNA from HP virus 15, is used as the labeled sample. Hybridization with the papilloma virus DNA present in the total DNA is obtained.
  • the above total DNA cleaved with BamHI is cloned in a ⁇ phage.
  • the corresponding clones i.e. the clones containing the papillomavirus DNA are identified by hybridization with the DNA from FIG. 1, possibly in combination with a DNA from the HP virus 15.
  • the insert of these clones is then subjected to further cloning in a plasmid vector, whereby a clone is obtained which contains the papillomavirus genome DL314-G.
  • the genome is confirmed by sequencing.
  • papillomavirus genomes are provided. They are named according to the DNAs used for their preparation, with: DL347-G, DL369-G, GA1 -3-G, GA3-1 -G, GA6-2-G or GA9-4-G.
  • Another object of the invention is a protein encoded by the above papillomavirus genome.
  • a protein is e.g. B. a major capsid protein (L1) or a minor capsid protein (L2).
  • L1 and L2 of the papilloma virus genome DL31 4-G are described as an example.
  • the HP virus 15, which is related to the DNA of FIG. 1, is used for this purpose. From this the complete sequence and the location of individual DNA coding for proteins Known areas.
  • These DNAs are identified on the papillomavirus genome DL31 4-G by parallel restriction cleavages of both genomes and subsequent hybridization with different fragments relating to the L1 or L2 coding DNA. They are confirmed by sequencing.
  • the DNA coding for L1 is designated DL314-G-L1-DNA and the DNA coding for L2 with DL31 4-G-L2-DNA.
  • the DNA coding for L1 or L2 is inserted into an expression vector.
  • E. coli examples of such for E. coli, yeast and animal cells are mentioned above.
  • vector pGEX-2T for expression in E. coli (cf. Kirnbauer, R. et al., Supra).
  • pGEX-2T-DL31 4-G-L1 or pGEX-2T-DL31 4-G-L2 is obtained.
  • these expression vectors express a glutathione S-transferase-L1 or glutathione S-transferase-L2 fusion protein. These proteins are purified in the usual way.
  • the bacculovirus or vaccinia virus system is called for a further expression of the above coding L1 or L2 DNA.
  • Expression vectors that can be used for this are, for example, pEV mod. and pSynwtVI " for the bacculovirus system (cf. Kirnbauer, R. et al., supra).
  • vectors with the vaccinia virus are" early "(p7. 5 k) or” late "(Psynth to call p1 1 K) promoter (cf. Hagensee, M., E.
  • the bacculovirus system is preferred DNA coding for L2 or L2 in pEV mod.
  • pEVmod.-DL31 4-G-L1 or pEVmod.-DL31 4-G-L2 is obtained.
  • a particle comprises an L1 protein
  • an L1 protein in the latter case it contains an L1 protein as well as an L1 protein.
  • a virus-like particle of the latter case is also obtained by standing DL31 4-G-L1 and DL314-G-L2 DNAs are inserted together into the expression vector pSynwtVI " and the pSynwtVI " DL31 4-G-L1 / L2 obtained is used to infect SF-9 insect cells.
  • the above virus-like particles are cleaned in the usual way. They also represent an object of the invention.
  • Another object of the invention is an antibody directed against an above protein or virus-like particle.
  • Such is produced in the usual way. It is described by way of example for the production of an antibody which is directed against a virus-like particle comprising L1 of DL314-G.
  • the virus-like particle BALB / c mice is injected subcutaneously. This injection is repeated every 3 weeks. About 2 weeks after the last injection, the serum containing the antibody is isolated and tested in the usual way.
  • the antibody is a monoclonal antibody.
  • spleen cells are removed from the mice after the fourth injection above and these are fused with myeloma cells in the usual way. The further cloning is also carried out according to known methods.
  • the present invention makes it possible to detect papilloma viruses, in particular in carcinomas of the skin.
  • the DNA according to the invention can be used as such or encompassed by a further DNA.
  • the latter can also be a papilloma virus gome or part of it.
  • the present invention also enables the provision of previously unknown papilloma viruses. These are found particularly in carcinomas of the skin. Furthermore, the invention provides proteins and virus-like particles which are due to these papillomaviruses. Antibodies are also provided which are directed against these proteins or particles.
  • the present invention thus enables diagnostic and therapeutic Take action on papilloma virus diseases. In addition, it provides the opportunity to build a vaccine against papillomavirus infections.
  • the present invention thus represents a breakthrough in the field of papilloma virus research.
  • Example 1 Identification of the papilloma virus genome DL314-G
  • the total DNA is isolated from a biopsy of a basal cell carcinoma. 1 ⁇ g of this DNA are cleaved with the restriction enzyme BamHI and electrophoresed in a 0.5% agarose gel. At the same time, 10 ⁇ g of the above DNA, which has not been cleaved, are also separated.
  • the agarose gel is subjected to a blotting process, whereby the DNA from the agarose gel is transferred to a nitrocellulose membrane. This is used in a hybridization process in which the above DNA from FIG. 1 is used in combination with HP virus 15 DNA as a p 32 -labeled sample. Hybridization with the blotted DNA is obtained.
  • the biopsy DNA obtained from Example 1 is cleaved with the restriction enzyme BamHI.
  • the fragments obtained are used in a ligase reaction in which the BamZAP Express vector, which has been cleaved and dephosphoryiated with BamHI, is also present.
  • the recombinant DNA molecules obtained here are in Bakte ⁇ ophagen packaged and used to infect bacteria.
  • the ZAP Express Vector Kit offered by Stratagene is used for these process steps.
  • the phage plaques obtained are then subjected to a hybridization process in which the p 32 -marked DNA from FIG. 1 used in Example 1 is used in combination with p 32 -marked HP virus 1 5 DNA. A hybridization with corresponding phage plaques is obtained.
  • the BamHI fragments of DL31 4-G are isolated from these and used together with a BamHI-cleaved, dephosphoryted plasmid vector, pBluesc ⁇ pt, in a further ligase reaction.
  • the recombinant DNA obtained -Molecules are used to transform bacteria, E. coli XLI -Blue.
  • a bacterial clone containing the papillomavirus genome DL314-G is identified by restriction cleavage or hybridization with the above DNA samples.
  • the plasmid of this bacterial clone is designated pBlue-DL31 4-G.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un ADN codant un peptide de protéine à capside principale de papillomavirus ou un génome de papillomavirus. L'invention concerne en outre des protéines codées par le génome de papillomavirus et des anticorps dirigés contre elles, ainsi que leur utilisation en matière de diagnostic, de thérapie et de vaccination.
EP98949901A 1997-08-13 1998-08-12 Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus Withdrawn EP1003877A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19735118A DE19735118C1 (de) 1997-08-13 1997-08-13 Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19735118 1997-08-13
PCT/DE1998/002379 WO1999009177A2 (fr) 1997-08-13 1998-08-12 Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus

Publications (1)

Publication Number Publication Date
EP1003877A2 true EP1003877A2 (fr) 2000-05-31

Family

ID=7838878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98949901A Withdrawn EP1003877A2 (fr) 1997-08-13 1998-08-12 Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus

Country Status (5)

Country Link
US (1) US6488935B1 (fr)
EP (1) EP1003877A2 (fr)
JP (1) JP2001514895A (fr)
DE (1) DE19735118C1 (fr)
WO (1) WO1999009177A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19735118C1 (de) * 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19840263C1 (de) * 1998-09-03 2000-05-25 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US20110014723A1 (en) * 2008-03-14 2011-01-20 Erdman Dean D Compositions and processes relating to human bocavirus
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593828B2 (fr) * 1986-01-31 1990-05-04 Pasteur Institut Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
EP0451550A3 (en) * 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19526386C1 (de) 1995-07-19 1997-01-02 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19648962C1 (de) 1996-11-26 1998-02-26 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19712541C1 (de) 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19735118C1 (de) * 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9909177A2 *

Also Published As

Publication number Publication date
US6488935B1 (en) 2002-12-03
WO1999009177B1 (fr) 1999-09-16
WO1999009177A3 (fr) 1999-08-12
DE19735118C1 (de) 1998-08-13
JP2001514895A (ja) 2001-09-18
WO1999009177A2 (fr) 1999-02-25

Similar Documents

Publication Publication Date Title
EP0809700B1 (fr) Particules semblables au virus du papillome, proteines de fusion et leur procede de production
DE19543553B4 (de) VP-Antigene des JC-Virus
DE69104380T2 (de) Vom genom des papillomavirus-hpv-39 abgeleitete dns-sequenzen, deren anwendung in der in vitro-diagnose und zur herstellung einer immunogenenzusammensetzung.
DE68922336T2 (de) Sonden für Papilloma-Virus (HPV49, HPV50, HPV54, HPV55), zu diesem Papilloma-Virus genetisch und immunologisch verwandte Produkte und in vitro Methoden zur Diagnose von Papilloma-Virusinfektionen und Herstellung von Antikörpern gegen diese Papilloma-Viren.
DE69531308T2 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE69631586T2 (de) Für menschliches papillomavirus stamm 18 kodierende dns
DE4415743C2 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19526386C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE69933875T2 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE19648962C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19735118C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE19712541C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
DE4447664C2 (de) Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
DE69528578T2 (de) Verändertes l2-protein des papillomavirus und damit gestellte viroide
DE10059631A1 (de) T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19840263C1 (de) Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
EP0354440A1 (fr) Papillomavirus humain type 57, son ADN, et protéines encodées par cette dernière
DE4332596A1 (de) Monoklonale Antikörper
DE19649606C1 (de) Systeme zur Bestimmung von Wirksubstanzen gegen HPV-assoziierte Karzinome
DE19905883C2 (de) Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
DE19518488C1 (de) Autoantigen, geeignet zur Feststellung einer Thromboseneigung
EP0449170A1 (fr) Protéine d'attachement cellulaire ayant une affinité pour la région régulatrice du papilloma virus humain de type 18
DE19526752A1 (de) Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
DE19520421A1 (de) Autoantigen, geeignet zur Feststellung einer Thromboseneigung
DE29824556U1 (de) Formulierung mit Papillomavirus-spezifischem Protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000308

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20040322

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040702